| Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis. | |
| | |
MedLine Citation:
|
PMID: 17255137 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: We present the results of the response to anti-tumour necrosis factor (anti-TNF) of 30 ankylosing spondylitis (AS) patients where we have complied with the BSR guidelines. METHOD: All patients had pre-assessments of Bath AS Disease Activity Index (BASDAIs) at two points a month apart prior to commencing anti-TNF. They then had 2 week and 2 month assessments followed by 3 monthly thereafter. BASDAI, visual analogue scales, blood count and erythrocyte sedimentation rate (ESR) were performed on each occasion. RESULTS: All patients had stable active disease at the pre-assessments with a mean BASDAI of 6.8. Twenty-nine patients showed a rapid and dramatic response with a mean BASDAI at 2 months assessment of 3.2 (P < 0.001). This was maintained for up to 20 months of follow up. Haemoglobin rose significantly (mean of 13.0 g/dl to 13.8) and the ESR dropped from 49 mm/h to 23 (both P < 0.001). Fifteen patients (51.7%) were able to stop their non-steroidal anti-inflammatory drugs (NSAIDs) and a further eight reduced them. CONCLUSION: Patients who fulfil the BSR guidelines for anti-TNF in AS have sustained active inflammatory disease prior to going onto etanercept or infliximab. Despite this, they show rapid, dramatic sustained responses to treatment, and over half are able to stop their NSAIDs. Any health economic analyses of anti-TNF in UK clinical practice need to take these observations into account. |
| | |
Authors:
|
K Gadsby; C Deighton |
Related Documents
:
|
20190687 - Elevated level of high-sensitivity c-reactive protein is important in determining progn... 6251407 - Csf "monoclonal" bands in chronic relapsing polyneuropathy. 19049707 - Crp measurement: does the assay matter in hemodialysis patients? 7662777 - Prognostic value of preoperative c-reactive protein concentration and white cell count ... 1837317 - Lipomatous hypertrophy of the cardiac interatrial septum: an unusual complication in lo... 18574487 - 'neurogenic' urinary tract dysfunction: don't overlook the bowel! |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2007-01-25 |
Journal Detail:
|
Title: Rheumatology (Oxford, England) Volume: 46 ISSN: 1462-0324 ISO Abbreviation: Rheumatology (Oxford) Publication Date: 2007 Mar |
Date Detail:
|
Created Date: 2007-02-19 Completed Date: 2007-05-09 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100883501 Medline TA: Rheumatology (Oxford) Country: England |
Other Details:
|
Languages: eng Pagination: 439-41 Citation Subset: AIM; IM |
Affiliation:
|
Department of Rheumatology, Derbyshire Royal Infirmary, Derby, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antibodies, Monoclonal / therapeutic use* Antirheumatic Agents / therapeutic use* Blood Sedimentation Female Follow-Up Studies Hemoglobins / metabolism Humans Immunoglobulin G / therapeutic use* Male Middle Aged Pain Measurement Patient Selection Practice Guidelines as Topic Receptors, Tumor Necrosis Factor / therapeutic use* Severity of Illness Index Spondylitis, Ankylosing / blood, drug therapy* Treatment Outcome Tumor Necrosis Factor-alpha / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Hemoglobins; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hodgkin's lymphoma in systemic lupus erythematosus.
Next Document: Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk excee...